Key result
PPAR-alpha agonist fenofibric acid restricts blood-brain barrier hyperpermeability induced by oxygen-glucose deprivation in mice.
Why the study?
The cellular targets of PPAR-alpha activation at the blood-brain barrier level remain largely unexplored despite reported neuroprotection in animal models.
PPAR-alpha activation with fenofibric acid protects against ischemia-induced blood-brain barrier hyperpermeability via direct effects on brain capillary endothelial cells.
Hypothesis-generating for fenofibric acid in ischemic BBB protection; requires further in vivo and clinical studies.
That promising neuroprotectants failed to demonstrate benefit against stroke highlights the great difficulties to translate preclinical pharmacological effects in clinical outcomes. Part of this hurdle implies the complex response to injury of the neurovascular unit increasing the cerebrovascular permeability at the level of the blood-brain barrier (BBB). Previous studies reported neuroprotection in animal models upon activation of the nuclear receptor PPARalpha(peroxisome proliferator-activated receptor)alpha, but the cellular targets at the BBB level remain largely unexplored. Here, to study whether PPAR-alpha activation acts on BBB permeability, we adapted a mouse BBB cell model to ischaemic conditions at the stage of occlusion defined in vitro as oxygen-glucose deprivation (OGD). This model consists of a co-culture of brain capillary endothelial cells (ECs) on a filter insert placed upon a rat glial cell culture. The EC monolayer permeability increase induced by 4 h of OGD was significantly restricted after treatment with the PPAR-alpha agonist fenofibric acid (FA) 24 h before or at the onset of OGD. Treatments of separated ECs or glial cells showed that this protective effect was conferred by BBB ECs but not glial cells. Furthermore, co-cultures with ECs from PPAR-alpha-deficient mice revealed that FA had no effect on OGD-induced hyperpermeability. No transcriptional modulation of classical PPAR-alpha target genes such as SOD, ICAM-1, VCAM-1, ACO, CPT-1, PDK-4 or ET-1 was observed in wild type mouse ECs. In conclusion, these results suggest that part of the preventive PPAR-alpha-mediated protection may occur via BBB ECs by limiting hyperpermeability.
No takes yet. Share an insight, caveat, or question.
Mysiorek et al. (2009) studied Stroke / Ischaemia (oxygen-glucose deprivation). PPAR-alpha agonist fenofibric acid (FA) was evaluated on Endothelial cell monolayer permeability increase. Treatment with the PPAR-alpha agonist fenofibric acid significantly restricted blood-brain barrier endothelial cell hyperpermeability induced by oxygen-glucose deprivation in a mouse model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: